| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e2abff6b77d95bd34f316c40dbc4758
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e95156255d5fe8b2923c544786e176 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-72 |
| filingDate |
2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a7d6ee04867279ffce1cff150662033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96c3316df6d2440007395e0c87e5b22f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df700cd9b4b397bb3d78dc916e776685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81923248cdf3c5a04bc011c379fe8e0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3402a8f5985c5fdc2ddcd1a660569b7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c50b6d5152acadfe9e4c81ba978010b6 |
| publicationDate |
2022-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022173743-A1 |
| titleOfInvention |
Compounds and methods for preventing, treating, or ameliorating airway disease |
| abstract |
The β2-adrenergic receptor (β 2 AR) is a primary target in the treatment of airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Since β-agonist treatment of airway disease can have severe side effects, compounds that attenuate the side effects of β-agonists have been identified via their ability to inhibit β 2 AR interaction with β-arrestins. These compounds are specific for the β 2 AR and effectively protect against the desensitization observed with β-agonist treatment in model cells and airway tissue. The present disclosure provides compounds and methods for treating airway disease, such as but not limited to COPD and/or asthma. |
| priorityDate |
2021-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |